Drug Type Small molecule drug |
Synonyms 4-Aminoclonidine, Apraclonidine, Apraclonidine hydrochloride (JAN/USP) + [7] |
Target |
Action agonists |
Mechanism adrenergic receptor agonists(Adrenergic receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (31 Dec 1987), |
Regulation- |
Molecular FormulaC9H11Cl3N4 |
InChIKeyOTQYGBJVDRBCHC-UHFFFAOYSA-N |
CAS Registry73218-79-8 |
Start Date01 Dec 2025 |
Sponsor / Collaborator |
Start Date07 Oct 2024 |
Sponsor / Collaborator |
Start Date21 Aug 2024 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01008 | Apraclonidine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ocular Hypertension | United States | 31 Dec 1987 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eye Redness | Phase 3 | United States | 21 Aug 2024 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 10 | iamzvmjovz(uofpydprug) = zgyjpxsdhb oylclpbgpn (hgglzyjjet ) View more | - | 31 May 2023 | |||
Not Applicable | 10 | fzzrrkyvra(xsdhqdkuxy) = ukztqxrzcu ztjmmjpwio (dzarpmuxpn ) View more | - | 03 May 2022 | |||
Not Applicable | 22 | skdmucwkij(sljtpwtlbk) = In 3 patients, post-IVL IOP spike in the control group rose by 40mmHg to 58-61mmHg, an IOP high enough to potentially cause an adverse event. With iopidine, the post-IVL IOP change decreased to spikes of 15-26mmHg for all three patients. mufaxslmxw (entagkijdn ) | - | 01 Apr 2009 |